Follow the link to Targeted Oncology for a breakdown of advances in treating chronic lymphocytic leukemia (CLL) as new agents, particularly next-generation BTK and PI3K inhibitors are utilized in clinical practice reported Jacqueline C. Barrientos, MD, MS at the 23rd...